This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ti, T Y
Right arrow Articles by Lee, H S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ti, T Y
Right arrow Articles by Lee, H S

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1985 October; 28(4): 540-543

Ceftriaxone therapy in bacteremic typhoid fever.

T Y Ti, E H Monteiro, S Lam and H S Lee

ABSTRACT

The efficacy and safety of ceftriaxone in the treatment of bacteremic typhoid fever was studied in 14 patients. Ceftriaxone at a dosage of 50 to 60 mg/kg per day was administered intravenously in two divided doses in 13 patients and as a single dose in 1 patient. When the two patients with medical complications causing persistent fever and the patient who was febrile during therapy were excluded from the calculations, the mean period of defervescence was 4 days. Five to eight days of ceftriaxone therapy was adequate for the patients who were cured. The 14 patients treated with ceftriaxone included 13 patients who were considered cured, although 1 was a convalescent carrier, and one patient who was a treatment failure. There were no relapses in the 11 patients who were monitored for 1 to 8 months. Both peak and trough concentrations of ceftriaxone were well above the ceftriaxone MICs for the Salmonella typhi strains isolated from the patients. We have demonstrated that ceftriaxone can be used successfully in the treatment of typhoid fever in some patients. The advantages of its use include rapid clinical response, short course of treatment, and lack of serious adverse drug reactions.


Antimicrob Agents Chemother. 1985 October; 28(4): 540-543




This article has been cited by other articles:

  • Dunne, E. F., Fey, P. D., Kludt, P., Reporter, R., Mostashari, F., Shillam, P., Wicklund, J., Miller, C., Holland, B., Stamey, K., Barrett, T. J., Rasheed, J. K., Tenover, F. C., Ribot, E. M., Angulo, F. J. (2000). Emergence of Domestically Acquired Ceftriaxone-Resistant Salmonella Infections Associated With AmpC {beta}-Lactamase. JAMA 284: 3151-3156 [Abstract] [Full Text]  
  • ROLSTON, K. V.I., RODRIGUEZ, S., MANSELL, P. W.A. (1988). Antimicrobial Therapy for Salmonella Infections in the Acquired Immunodeficiency Syndrome (AIDS). ANN INTERN MED 108: 309-309 [Abstract]